Canada markets open in 2 hours 42 minutes

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7500+0.6800 (+16.71%)
At close: 04:00PM EDT
4.6500 -0.10 (-2.11%)
Pre-Market: 06:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.0700
Open4.2000
Bid0.0000 x 1000
Ask0.0000 x 1000
Day's Range4.0900 - 5.8500
52 Week Range1.7100 - 14.4200
Volume6,802,490
Avg. Volume1,134,666
Market Cap346.783M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

    -- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to molecular responses in advanced colorectal cancer (CRC) patients and associated with extended overall survival, which has been observed in follow-up to the Phase 1/2 study -- -- GRANITE now in a randomized, controlled Phase 2/3 trial in newly diagnosed metastatic, microsatellite-stable colorectal cancer (

  • GlobeNewswire

    Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

    -- Expert in virology, immunology and vaccine development’s appointment effective August 12 -- Dr. Lawrence "Larry" Corey Dr. Lawrence "Larry" Corey, M.D., expert in virology, immunology and vaccine development and incoming Board Member of Gritstone bio, Inc. EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced the appointment of Lawrence “Larry” Core

  • GlobeNewswire

    Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update

    -- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA (samRNA) -- -- New credit facility provides financial flexibility entering period of multiple potent